

Personal Information

Web: <https://avesis.marmara.edu.tr/14010>

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing**
KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündoğdu A., SEVER N., Ayhan M., Çelebi A., Majidova N., et al.
Journal of Chemotherapy, 2024 (SCI-Expanded)
- II. **PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study**
Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., Değerli E., Özdemir Ö., İnal A., Ocak B., et al.
Journal of Geriatric Oncology, vol.14, no.8, 2023 (SCI-Expanded)
- III. **PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score**
BAYOĞLU İ. V., Hüseyinov J., Topal A., Sever N., Majidova N., Çelebi A., Yaşar A., ARIKAN R., Işık S., Hacıoğlu M. B., et al.
Journal of Clinical Medicine, vol.12, no.19, 2023 (SCI-Expanded)
- IV. **Major and minor salivary gland cancers: A multicenter retrospective study**
Hacıoglu M. B., ERDOĞAN B., Bardakçı M., Algin E., Gulbagcı B., Hacibekiroğlu I., HAMDARD J., ÖLMEZ Ö. F., Akkus H., Oksuzoglu B., et al.
Head and Neck, vol.45, no.7, pp.1643-1653, 2023 (SCI-Expanded)
- V. **External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database**
Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., ARIKAN R., Hızal M., Küçükarda A., Sever Ö. N., et al.
Clinical Genitourinary Cancer, vol.21, no.1, pp.175-182, 2023 (SCI-Expanded)
- VI. **The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study**
Atci M. M., Akagunduz B., Demir M., Arıkan R., Ay S., Ozer M., Ayhan M., Cil I., DEMİR N., Ozyurt N., et al.
JOURNAL OF CHEMOTHERAPY, vol.35, no.1, pp.19-28, 2023 (SCI-Expanded)
- VII. **Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma**
Basoglu T., Babacan N. A., Ozturk F. E., ARIKAN R., DEMİRCAN N., Telli T. A., Ercelep O., DANE F., Yumuk P. F.
Indian Journal of Cancer, vol.60, no.2, pp.179-184, 2023 (SCI-Expanded)
- VIII. **Role of baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment**
AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S., Sariyar N., Isik S., Arıkan R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., et al.
ANNALS OF NUCLEAR MEDICINE, vol.36, no.11, pp.964-975, 2022 (SCI-Expanded)
- IX. **Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy**
AKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arıkan R., BAŞOĞLU TÜYLÜ T., Kaya S., Ercelep O.,

Babacan N. A., et al.

FUTURE ONCOLOGY, vol.18, pp.2425-2439, 2022 (SCI-Expanded)

- X. **Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy** Valor predictivo de los índices 18F-FDG PET/TC sobre la carga tumoral residual en pacientes con cáncer de mama extenso tratadas con quimioterapia neoadyuvante
Başoğlu T., ÖZGÜVEN S., ŞAHİN ÖZKAN H., Çınar M., Köstek O., Can Demircan N., ARIKAN R., AKIN TELLİ T., Ercelep Ö., KAYA H., et al.
Revista Espanola de Medicina Nuclear e Imagen Molecular, vol.41, pp.171-178, 2022 (SCI-Expanded)
- XI. **Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma**
AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., Yasar A., Majidova N., Celebi A., EROL B., et al.
Nutrition and Cancer, vol.74, no.7, pp.2499-2507, 2022 (SCI-Expanded)
- XII. **Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma**
BAŞOĞLU TÜYLÜ T., AKAR K. E., BAĞCI ÇULÇI P., Babacan N. A., ÖZTÜRK M. A., ÖZTÜRK F. E., DEMİRCAN N. C., Arikan R., AKIN TELLİ T., Ercelepl O., et al.
BALKAN MEDICAL JOURNAL, vol.39, no.1, pp.12-20, 2022 (SCI-Expanded)
- XIII. **FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer**
Ay S., Atci M. M., Arikan R., Dulgar O., Ozyukseler D. T., Paksoy N., DOĞAN İ., ÖZTOSUN B., Tastekin D., Oven B. B., et al.
JOURNAL OF CHEMOTHERAPY, vol.34, no.7, pp.465-471, 2022 (SCI-Expanded)
- XIV. **Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?**
Dulgar O., Oven B. B., Atci M. M., Arikan R., Ay S., Ayhan M., Selvi O., Ozyukseler D. T., Bayram E., ÖZCAN E., et al.
EXPERT REVIEW OF ANTICANCER THERAPY, vol.22, no.7, pp.773-780, 2022 (SCI-Expanded)
- XV. **Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database**
Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., Arikan R., Arslan C., Taban H., Kucukarda A., et al.
FUTURE ONCOLOGY, vol.17, no.35, pp.4861-4869, 2021 (SCI-Expanded)
- XVI. **Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma**
Ercelep O., Alan O., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Simsek E. T., Babacan N. A., Kaya S., DANE F., et al.
TUMORI J, vol.107, no.3, pp.231-237, 2021 (SCI-Expanded)
- XVII. **Clinicopathologic Features of Large Cell Neuroendocrine Carcinoma of Lung**
Arikan R., Demircan N., Basoglu T., Telli T. A., Ercelep O., Dane F., Yumuk P. F.
JOURNAL OF THORACIC ONCOLOGY, vol.16, no.3, 2021 (SCI-Expanded)
- XVIII. **Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience**
Alan O., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Ercelep O., Kaya S., Babacan N. A., ATASOY B. M., BOZKURT S., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.2, pp.329-339, 2021 (SCI-Expanded)
- XIX. **A rare case of gastric cancer with bilateral breast metastasis during pregnancy**
Başoğlu Tüylü T., Akın Telli T., Demircan N. C., Arikan R., Ercelep O., Özgüven S., Soysal S., Memişoğlu A., Dane F., Yumuk P. F.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.27, no.1, pp.220-226, 2021 (SCI-Expanded)
- XX. **QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer**

DEMİRCAN N. C., Akın Telli T., BAŞOĞLU TÜYLÜ T., Arikan R., Kocakaya D., Şahin A. A., Ercelep Ö., DANE F., YUMUK P. F.

CURRENT PROBLEMS IN CANCER, vol.44, no.6, 2020 (SCI-Expanded)

- XXI. **Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?**

Alan O., AKIN TELLİ T., Aktas B., KOCA S., ÖKTEN İ. N., Hasanov R., BAŞOĞLU TÜYLÜ T., Arikan R., DEMİRCAN N. C., Ercelep O., et al.

WORLD JOURNAL OF SURGICAL ONCOLOGY, vol.18, no.1, 2020 (SCI-Expanded)

- XXII. **Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib**

DEMİRCAN N. C., Alan O., Tuylu T. B., Telli T. A., Arikan R., ÇİÇEK F. C., Ercelep O., Ozturk M. A., Cetin İ., ERGELEN R., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1147-1155, 2020 (SCI-Expanded)

- XXIII. **A rare case of primary rectal choriocarcinoma and review of the literature**

Telli T. A., Demircan N. C., Alan O., Tuylu T. B., Arikan R., Ercelep O., Atıcı A. E., Ergelen R., Seven I. E., Babacan N. A., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.4, pp.989-994, 2020 (SCI-Expanded)

- XXIV. **Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?**

Tuylu T. B., DEMİRCAN N. C., Arikan R., Telli T. A., Alan O., Ercelep O., BOZKURTLAR E., Kocakaya D., Kaya S., Babacan N., et al.

JOURNAL OF THORACIC ONCOLOGY, vol.14, no.10, 2019 (SCI-Expanded)

Articles Published in Other Journals

- I. **Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib**

ARIKAN R., Üstün H. S., Demircan N. C., Işık S., Telli T. A., Yaşar A., Çelebi A., Majidova N., Sever N., ÇELİKEL Ç., et al.
Journal of Oncological Science, vol.9, no.2, pp.53-61, 2023 (Scopus)

- II. **Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis**

Ay S., Atci M. M., ARIKAN R., Dülger Ö., Tataroğlu Özyükseler D., Gümüş M.
Journal of Oncological Science, vol.9, no.1, pp.8-14, 2023 (Scopus)

- III. **Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma**

BAŞOĞLU TÜYLÜ T., ÖZGÜVEN S., ENGÜR C. Ö., AKAGÜNDÜZ F., DEMİRCAN N. C., ARIKAN R., TEMİZ F., ŞENGÜN S., IŞIK S., AKIN TELLİ T., et al.

Eurasian Journal of Medical Investigation, vol.7, no.1, pp.32-41, 2022 (Peer-Reviewed Journal)

- IV. **Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib**

DEMİRCAN N. C., ENGÜR C. Ö., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., Arikan R., Yasar A., Celebi A., Alan O., Isik S., ÖZGÜVEN S., et al.

TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.37, no.4, pp.379-387, 2022 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **R1 rezeksiyon ile opere edilmiş pankreas kanseri hastalarında adjuvan kemoradyoterapi zamanlamasının sağkalım sonuçlarına etkisi**

ARIKAN R., ALKIŞ H.

2. Ankara Hematoloji ve Onkoloji Günleri, Ankara, Turkey, 04 February 2022, pp.85-88

- II. **Does insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?**

Alan O., AKIN TELLİ T., Aktas B., KOCA S., ÖKTEN İ. N., BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., Ercelep O., UĞURLU M. Ü., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 10 - 14 December 2019, vol.80

- III. **S 033: Survival Data and Prognostic Factors in HER2/Neu Positive Metastatic Breast Cancer Patients Undergoing TDM1: A Single Center Experience**
ARIKAN R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.
3rd National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019
- IV. **Multiple Primary Tumors: Single Center Experience**
BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.
6th CONGRESS OF THEMEDITERRANEAN MULTIDISCIPLINARY ONCOLOGY FORUM and 3rd International Congress on Oncological Sciences (ICONS), Antalya, Turkey, 27 November - 01 December 2019, vol.5, pp.1
- V. **SS 12: Metastatik Akciğer Adenokanserinde Osimertinib Kullanımı: Tek Merkez Deneyimi**
BAŞOĞLU TÜYLÜ T., ARIKAN R., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.
Kanser Güncel Akciğer Kanseri Sempozyumu, Turkey, 22 - 23 November 2019
- VI. **Metastatik Akciğer Adenokanserinde Osimertinib Kullanımı: Tek Merkez Deneyimi**
BAŞOĞLU TÜYLÜ T., ARIKAN R., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
Kanserde Güncel Gelişmeler 2019 Akciğer Kanseri Sempozyumu, Turkey, 22 - 23 November 2019
- VII. **SS 104: İlerlemiş Mesane Kanseri Prognostik Faktörler**
ALACA TOPÇU Z., ÖZTÜRK M. A., YILDIRIM M. E., ARIKAN R., BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., AKIN TELLİ T., ERCELEP O., DANE F., YUMUK P. F.
14. Üroonkoloji Kongresi, Turkey, 6 - 10 November 2019
- VIII. **Survival Data and Prognostic Factors in HER2/Neu Positive Metastatic Breast Cancer Patients Undergoing TDM1: A Single Center Experience**
ARIKAN R., DEMİRCAN N. C., BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ERCELEP Ö., DANE F., YUMUK P. F.
3th National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019
- IX. **S 031: Prognostic Value of GRIm Scores in Pancreatic Cancer**
BAŞOĞLU TÜYLÜ T., DEMİRCAN N. C., ARIKAN R., AKIN TELLİ T., ERCELEP O., Babacan N. A., DANE F., YUMUK P. F.
3rd National Immunotherapy and Oncology Congress, Turkey, 30 October - 03 November 2019
- X. **NADIR VAKA: MESANENİN MÜSİNÖZ ADENOKANSERİ**
BAŞOĞLU TÜYLÜ T., AKIN TELLİ T., ALAN Ö., ARIKAN R., ERCELEP Ö., KAYA S., BABACAN N., FİLİNTE D., DANE F., YUMUK P. F.
23.ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019
- XI. **PALATIN TONSİL METASTAZ! YAPMIŞ PRIMER AKCİĞER PLEOMORFİK SARKOMU, OLGU SUNUMU**
ARIKAN R., ALAN Ö., AKIN TELLİ T., BAŞOĞLU TÜYLÜ T., ERCELEP Ö., KAYA S., BABACAN N., DANE F., YUMUK P. F.
23.ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019

Metrics

Publication: 39

Citation (WoS): 23

Citation (Scopus): 35

H-Index (WoS): 3

H-Index (Scopus): 4